1. Home
  2. ANIP vs WOOF Comparison

ANIP vs WOOF Comparison

Compare ANIP & WOOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANIP
  • WOOF
  • Stock Information
  • Founded
  • ANIP 2001
  • WOOF 1965
  • Country
  • ANIP United States
  • WOOF United States
  • Employees
  • ANIP N/A
  • WOOF N/A
  • Industry
  • ANIP Biotechnology: Pharmaceutical Preparations
  • WOOF Other Specialty Stores
  • Sector
  • ANIP Health Care
  • WOOF Consumer Discretionary
  • Exchange
  • ANIP Nasdaq
  • WOOF Nasdaq
  • Market Cap
  • ANIP 1.4B
  • WOOF N/A
  • IPO Year
  • ANIP N/A
  • WOOF 2021
  • Fundamental
  • Price
  • ANIP $65.40
  • WOOF $2.82
  • Analyst Decision
  • ANIP Strong Buy
  • WOOF Buy
  • Analyst Count
  • ANIP 8
  • WOOF 8
  • Target Price
  • ANIP $80.13
  • WOOF $3.75
  • AVG Volume (30 Days)
  • ANIP 283.5K
  • WOOF 6.1M
  • Earning Date
  • ANIP 08-05-2025
  • WOOF 06-05-2025
  • Dividend Yield
  • ANIP N/A
  • WOOF N/A
  • EPS Growth
  • ANIP N/A
  • WOOF N/A
  • EPS
  • ANIP N/A
  • WOOF N/A
  • Revenue
  • ANIP $674,068,000.00
  • WOOF $6,080,721,000.00
  • Revenue This Year
  • ANIP $30.52
  • WOOF $0.04
  • Revenue Next Year
  • ANIP $7.40
  • WOOF $1.41
  • P/E Ratio
  • ANIP N/A
  • WOOF N/A
  • Revenue Growth
  • ANIP 30.27
  • WOOF N/A
  • 52 Week Low
  • ANIP $52.50
  • WOOF $2.23
  • 52 Week High
  • ANIP $77.00
  • WOOF $6.29
  • Technical
  • Relative Strength Index (RSI)
  • ANIP 58.76
  • WOOF 45.48
  • Support Level
  • ANIP $63.80
  • WOOF $2.67
  • Resistance Level
  • ANIP $67.42
  • WOOF $2.84
  • Average True Range (ATR)
  • ANIP 1.75
  • WOOF 0.14
  • MACD
  • ANIP 0.60
  • WOOF 0.02
  • Stochastic Oscillator
  • ANIP 78.62
  • WOOF 87.56

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Share on Social Networks: